Is NCT07731789 recruiting in Seattle, WA?

Yes, NCT07731789 is currently recruiting participants at its Seattle, WA location. This classic follicular lymphoma clinical trial is actively enrolling qualified participants.

How do I join the classic follicular lymphoma clinical trial in Seattle?

To join this clinical trial in Seattle, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Seattle clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Classic Follicular Lymphoma Clinical Trial in Seattle, WA

About This Classic Follicular Lymphoma Study in Seattle

This phase II trial tests how well tafasitamab and rituximab works for the treatment of newly diagnosed follicular lymphoma. Tafasitamab is a monoclonal antibody. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving tadasitamab and rituximab may work well to treat patients with newly diagnosed follicular lymphoma.

Sponsor: University of Washington

Who Can Participate

Inclusion Criteria

Age ≥ 18 years old

Patients must have histologic confirmation of follicular lymphoma (FL) (grade 1, 2, and 3A or classic follicular lymphoma)

Meeting any one of the following criteria for therapy initiation:

Involvement of ≥ 3 nodal sites, each with diameter of ≥ 3 cm.

Any nodal or extranodal tumor mass with a diameter of ≥ 7 cm.

B symptoms (fever ≥ 38 degrees Celsius of unclear etiology, night sweats, weight loss \> 10% within the prior 6 months) attributed to FL.

Risk of local compressive symptoms that may result in organ compromise.

Splenomegaly with the inferior margin below the umbilical line or splenic lesion without splenomegaly.

Significant cytopenia (absolute neutrophil count \< 1500/mm3, platelets \< 100,000/uL, hemoglobin \< 10 g/dL)

Leukemia (\> 5,0000/uL circulating lymphocytes)

Pleural effusion or ascites attributed to lymphoma

Have measurable nodal disease, including at least 1 disease site measuring at least 1.5 cm in longest dimension on CT or fludeoxyglucose (FDG)-PET, or a FDG-avid extranodal measurable site measuring at least 1.0 cm in longest dimension. Measurable disease also includes spleen size more than 13 cm in vertical length

Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

Absolute neutrophil count ≥ 1500/mm\^3 (unless due to lymphoma involvement of the bone marrow or spleen)

Platelets ≥ 75,000/mm\^3 (unless due to bone marrow involvement by lymphoma)

Hemoglobin ≥ 8 g/dL (unless due to bone marrow involvement by lymphoma)

Total bilirubin ≤ 2.0 mg/dL, except for patients with documented lymphoma involvement of liver or with a known history of Gilbert's disease

Alkaline phosphatase/aspartate aminotransferase (AST)/(serum glutamic-oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT)(serum glutamate pyruvate transaminase \[SGPT\]) ≤ 3 × institutional upper limit of normal, except for patients with documented liver involvement

Creatinine clearance ≥ 30 ml/min

Fertile male and women of child bearing potential (WOCBP) patients must be willing to use highly effective contraceptive methods from study recruitment to at least 6 months after the last dose of study treatment

Ability to understand and willingness to sign a written informed consent document

Exclusion Criteria

FL grade 3B or transformed FL

Patients receiving any other investigational agents

Patients with known central nervous system involvement of lymphoma

History of a second primary malignancy that could affect compliance with the protocol or interpretation of results except with permission of the principal investigator. Malignancies treated curatively or at low-risk of progressing at the judgment of the primary investigator (PI) may be included

Known active and uncontrolled bacterial, viral, fungal, mycobacterial, or other infection at study enrollment

Uncontrolled intercurrent illness such as: history of myocardial infarction (MI) in the last 6 months, congestive heart failure New York Heart Association (NYHA) Class III-IV, uncontrolled or symptomatic arrhythmia, stroke in last 6 months, liver cirrhosis, and autoimmune disorder requiring immunosuppression or long-term corticosteroids (\> 10 mg daily prednisone equivalent)

Prior use of any monoclonal antibody within 4 weeks before the first administration

Breastfeeding or pregnant women

Serologic status reflecting active hepatitis B or C infection. Patients that are positive for hepatitis B core antibody, hepatitis B surface antigen (HBsAg), or hepatitis C antibody are eligible if the corresponding polymerase chain reaction (PCR) test is negative prior to enrollment. Hepatitis B core antibody (+) patients without evidence of HBsAg or Hep B PCR (+) are eligible with appropriate Hepatitis B reactivation prophylaxis as per institutional guidelines

History of human immunodeficiency virus (HIV) infection uncles the viral load is undetectable and CD4 count is at least 400

History or evidence of rare hereditary problems of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption

Major surgery (excluding lymph node biopsy) within 28 days prior to signing the informed consent form (ICF) unless the participant is recovered at the time of signing the ICF

Any systemic anti-lymphoma and/or investigational therapy within 28 days prior to the start of cycle 1

Administration of a live vaccine within 28 days prior to the start of study treatment (cycle 1 day 1)

History of hypersensitivity to compounds of similar biological or chemical composition to tafasitamab, immunomodulatory drugs, rituximab, other monocolonal antibodies (mAbs), and/or the excipients contained in the study drug formulations

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Seattle?

Yes, this clinical trial (NCT07731789) has an active research site in Seattle, WA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Classic Follicular Lymphoma Treatment Options in Seattle, WA

If you're searching for classic follicular lymphoma treatment options in Seattle, WA, this clinical trial (NCT07731789) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Seattle research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced classic follicular lymphoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all classic follicular lymphoma clinical trials near you to find additional studies recruiting in your area.

Classic Follicular Lymphoma Clinical Trial in Seattle, WA

Expert Care in Seattle

IRB Approved

No-Cost Care

Apply for This Seattle Location

Why Participate?

Simple Process